Table 4.

Summary of all adverse events by treatment.

	Number (%) of subjects
	Placebo (N = 5)	3 mg/kg Drisapersen (N = 6)	6 mg/kg Drisapersen (N = 6)	9 mg/kg Drisapersen (N = 3)	Total (N = 20)
Any AE by phase
Treatment emergent	2 (40)	6 (100)	6 (100)	3 (100)	17 (85)
Follow-up	2 (40)	3 (50)	4 (67)	0	9 (45)
Drug related AEs (per investigator judgment)	1 (20)	5 (83)	5 (83)	3 (100)	14 (70)
AEs of special interest
Injection site reaction	1 (20)	4 (67)	5 (83)	3 (100)	13 (65)
Renal toxicity	0	0	0	1 (33)	1 (5)
Inflammation	0	0	1 (17)	3 (100)	4 (20)